CPSE:NZYM B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. More Details


Snowflake Analysis

Solid track record established dividend payer.


Similar Companies

Share Price & News

How has Novozymes's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NZYM B has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.5%

NZYM B

-2.2%

DK Chemicals

-3.1%

DK Market


1 Year Return

23.9%

NZYM B

5.3%

DK Chemicals

28.5%

DK Market

Return vs Industry: NZYM B exceeded the Danish Chemicals industry which returned 5.3% over the past year.

Return vs Market: NZYM B underperformed the Danish Market which returned 28.5% over the past year.


Shareholder returns

NZYM BIndustryMarket
7 Day-4.5%-2.2%-3.1%
30 Day-1.8%1.7%3.4%
90 Day1.3%1.8%5.7%
1 Year25.7%23.9%8.7%5.3%30.9%28.5%
3 Year16.7%11.5%5.6%-4.6%48.2%37.0%
5 Year32.6%23.3%37.4%16.7%69.8%48.6%

Price Volatility Vs. Market

How volatile is Novozymes's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Novozymes undervalued compared to its fair value and its price relative to the market?

35.49x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: NZYM B (DKK391.5) is trading above our estimate of fair value (DKK251.82)

Significantly Below Fair Value: NZYM B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: NZYM B is poor value based on its PE Ratio (35.6x) compared to the XE Chemicals industry average (20.7x).

PE vs Market: NZYM B is poor value based on its PE Ratio (35.6x) compared to the Danish market (16.3x).


Price to Earnings Growth Ratio

PEG Ratio: NZYM B is poor value based on its PEG Ratio (6x)


Price to Book Ratio

PB vs Industry: NZYM B is overvalued based on its PB Ratio (10.2x) compared to the XE Chemicals industry average (1.6x).


Next Steps

Future Growth

How is Novozymes forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

5.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NZYM B's forecast earnings growth (5.9% per year) is above the savings rate (0.3%).

Earnings vs Market: NZYM B's earnings (5.9% per year) are forecast to grow slower than the Danish market (12% per year).

High Growth Earnings: NZYM B's earnings are forecast to grow, but not significantly.

Revenue vs Market: NZYM B's revenue (4.3% per year) is forecast to grow slower than the Danish market (6.5% per year).

High Growth Revenue: NZYM B's revenue (4.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NZYM B's Return on Equity is forecast to be high in 3 years time (28%)


Next Steps

Past Performance

How has Novozymes performed over the past 5 years?

2.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NZYM B has high quality earnings.

Growing Profit Margin: NZYM B's current net profit margins (21.6%) are higher than last year (21.4%).


Past Earnings Growth Analysis

Earnings Trend: NZYM B's earnings have grown by 2.2% per year over the past 5 years.

Accelerating Growth: NZYM B's earnings growth over the past year (0.8%) is below its 5-year average (2.2% per year).

Earnings vs Industry: NZYM B earnings growth over the past year (0.8%) exceeded the Chemicals industry -9.8%.


Return on Equity

High ROE: NZYM B's Return on Equity (28.6%) is considered high.


Next Steps

Financial Health

How is Novozymes's financial position?


Financial Position Analysis

Short Term Liabilities: NZYM B's short term assets (DKK6.6B) exceed its short term liabilities (DKK4.3B).

Long Term Liabilities: NZYM B's short term assets (DKK6.6B) exceed its long term liabilities (DKK5.0B).


Debt to Equity History and Analysis

Debt Level: NZYM B's debt to equity ratio (45.5%) is considered high.

Reducing Debt: NZYM B's debt to equity ratio has increased from 11.8% to 45.5% over the past 5 years.

Debt Coverage: NZYM B's debt is well covered by operating cash flow (78.9%).

Interest Coverage: NZYM B's interest payments on its debt are well covered by EBIT (152.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Novozymes's current dividend yield, its reliability and sustainability?

1.34%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: NZYM B's dividend (1.34%) is higher than the bottom 25% of dividend payers in the Danish market (1.33%).

High Dividend: NZYM B's dividend (1.34%) is low compared to the top 25% of dividend payers in the Danish market (3.58%).


Stability and Growth of Payments

Stable Dividend: NZYM B's dividends per share have been stable in the past 10 years.

Growing Dividend: NZYM B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (47.7%), NZYM B's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: NZYM B's dividends in 3 years are forecast to be covered by earnings (51.2% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Ester Baiget

0.67

Tenure

Ms. Ester Baiget serves as Chief Executive Officer at Novozymes A/S Since February 1, 2020 and its President since 2020. She serves as the EMEA Commercial Director for Dow Elastomers, Electrical and Teleco ...


Leadership Team

NamePositionTenureCompensationOwnership
Lars Green
Executive VP & CFO1.08yrskr.4.20m0.00036%
DKK 393.9k
Thomas Videbaek
EVP of Strategy & Business Transfotmationno datakr.10.50mno data
Anders Lund
Executive Vice President of Consumer Biosolutions4.67yrskr.7.70m0.000050%
DKK 54.7k
Tina Fanø
Executive Vice President of Agriculture & Industrial Biosolutions4.67yrskr.7.60m0.0036%
DKK 4.0m
Ester Baiget
President & CEO0.67yrno datano data
Graziela Chaluppe dos Malucelli
Executive Vice President of Operations0.75yrno datano data
Tobias Bjorklund
Head of Investor Relationsno datano datano data
Tue Micheelsen
Vice President of Global Sales & Marketingno datano datano data
Pedro Fernandes
Head of Corporate Affairs & Sustainability - Novozymes Latin Americano datano datano data
Sebastian Søderberg
VP and Head of New Business Development - Incubations & Acquisitionsno datano datano data
Claus Fuglsang
CSO and Executive VP of Research & Development0.75yrno datano data
Adam Monroe
President of North American Region11.17yrsno datano data

1.1yrs

Average Tenure

52yo

Average Age

Experienced Management: NZYM B's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mathias Uhlén
Independent Director13.75yrskr.500.00k0.00023%
DKK 251.6k
Lars Køppler
Employee Representative Director10.75yrskr.500.00k0.00013%
DKK 142.2k
Jørgen Rasmussen
Independent Chairman3.67yrskr.1.75m0.00071%
DKK 776.8k
Cornelis de Jong
Vice Chairman0.67yrno datano data
Kim Stratton
Independent Director3.67yrskr.750.00kno data
Kasim Kutay
Director3.67yrskr.500.00kno data
Lena Holskov
Employee Representative Director7.67yrskr.500.00k0.00039%
DKK 426.7k
Anders Knudsen
Employee Representative Director7.67yrskr.500.00k0.00013%
DKK 142.2k
Sharon James
Director0.67yrno datano data
Heine Dalsgaard
Director0.67yrno datano data

3.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: NZYM B's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Novozymes A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Novozymes A/S
  • Ticker: NZYM B
  • Exchange: CPSE
  • Founded: 1925
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: kr.109.405b
  • Shares outstanding: 280.24m
  • Website: https://www.novozymes.com

Number of Employees


Location

  • Novozymes A/S
  • Krogshoejvej 36
  • Bagsvaerd
  • Capital Region of Denmark
  • 2880
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVZM.FOTCPK (Pink Sheets LLC)YesSeries B SharesUSUSDNov 2000
NZM2DB (Deutsche Boerse AG)YesSeries B SharesDEEURNov 2000
NZYM BCPSE (OMX Nordic Exchange Copenhagen)YesSeries B SharesDKDKKNov 2000
0Q4ULSE (London Stock Exchange)YesSeries B SharesGBDKKNov 2000
NZYMBCBATS-CHIXE (BATS 'Chi-X Europe')YesSeries B SharesGBDKKNov 2000
NZYMBSWX (SIX Swiss Exchange)YesSeries B SharesCHCHFNov 2000
NZYMWBAG (Wiener Boerse AG)YesSeries B SharesATEURNov 2000
NZYM NBMV (Bolsa Mexicana de Valores)YesSeries B SharesMXMXNNov 2000
NVZM.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDFeb 2003

Biography

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefactio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 22:32
End of Day Share Price2020/10/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.